Sie sind auf Seite 1von 4

Evolutionary Development Success stories Failures

One such success story One of the failures of the


In the late 1960s, scientists stemmed from the gene therapy happened
first demonstrated the Nationwide Children’s with the first humans to
feasibility of incorporating Hospital, Ohio. In this receive gene therapy took
new genetic functions in 2017 study published by place in 1970. It was
mammalian cells. They used the research team in New administered to two very
several methods, One England Journal of young West German
involved injecting genes with Medicine, 15 patients with sisters suffering from
a micropipette directly into a spinal muscular atrophy hyperargininemia, an
living mammalian cell. type 1 (SMA1) received a extremely rare genetic
Another exposed cells to a single dose of gene disorder that prevents the
precipitate of DNA containing therapy with a goal of production of arginase.
the desired genes. functionally replacing the This is an enzyme that
mutated gene. Subjects helps prevent the build up
One of the first people to that underwent gene of arginine in bodily fluids.
report the direct therapy showed signs of Any accumulation can
incorporation of functional motor improvement which cause brain damage,
DNA into a mammalian cell are otherwise absent epilepsy and other
was Lorraine Kraus at the when untreated. A neurological and muscular
University of Tennessee. she significant part of this gene
problems. Each sister
managed to genetically alter therapy success can be received an injection of a
the haemoglobin of cells attributed to an rabbit virus (Shope
from bone marrow taken unassuming, vital papilloma) known to induce
from a patient with sickle-cell contributor – a delivery the production of arginase.
anaemia in 1961. Seven virus. The injection was given as
years later, Theodore a last desperate measure
Friedmann, Jay Seegmiller Year 2017, Sickle-cell to rescue the children. The
and John Subak-Sharpe at cure, in March, treatment was carried out
the National Institutes of researchers announced by Stanfield Rogers, an
Health (NIH), Bethesda, that a teenage boy in American physician,
successfully corrected France had been cured of together with H. G.
genetic defects associated sickle-cell disease after Terheggen, a German
with Lesch-Nyhan syndrome, receiving an experimental paediatrician. They took the
a debilitating neurological gene therapy developed risk based on observations
disease. They did this by by Bluebird Bio. Caused Rogers had previously
adding foreign DNA to by a single genetic made with some laboratory
cultured cells collected from mutation, sickle-cell is an technicians at Oak Ridge
patients suffering from the inherited blood disorder National Laboratory who
disease. The first humans to that affects 100,000 became infected with the
receive gene therapy took people in the U.S. and rabbit virus when working
place in 1970. It was millions around the world. with it. None of the
administered to two very Scientists removed stem technicians experienced ill-
young West German sisters cells from the boy’s bone effects from the virus but
suffering from marrow and modified them had abnormally low levels
hyperargininemia, an in the lab by introducing of arginine in their blood.
extremely rare genetic copies of a gene to This was apparent even in
disorder that prevents the prevent his red blood cells a technician whose last
production of arginase. But from becoming “sickled.” exposure to the virus had
Disappointingly none of the When the treated cells been 20 years before.
sisters responded to the were infused back into his Rogers connected the
treatment. body, they began to make technicians’ abnormal
normal blood cells. More arginine levels with a gene
In the early 1970s, A new than two years after in the rabbit virus which
pathway for gene therapy treatment, the patient has was known to encourage
opened up with the enough normal red blood the production of arginase
development of genetic cells to evade any side in rabbits. By giving the
engineering. The technique effects of the disorder. rabbit virus to the girls,
provided two key tools. Rogers hoped to transfer
Firstly, a means to clone Cancer killers genetic instructions to their
specific disease genes. This year the FDA cells to produce arginase.
Secondly, an efficient approved two pioneering After the two sisters were
method for gene transfer. US treatments, Kymriah and treated a third sister was
scientists Theodore Yescarta, that use a born afflicted with
Friedmann and Richard patient’s own immune hyperargininemia. She was
Roblin hightlighted the cells to fight rare types of also injected with the virus.
potential of the technology cancer. Called CAR-T Disappointingly none of the
for gene therapy. The therapies, these “living sisters responded to the
technique was first tried out drugs” are made by treatment.
in the case of beta- extracting T cells from
thalassemia. patients and genetically
engineering them to go
In the 1980s Gene therapy after and destroy cancer
entered a new era, the cells. The cells are then
discovery of retroviruses infused back into the body.
which proved a much more So far, these therapies are
efficient tool for gene being tested only in a
transfer. The first suitable handful of lethal cancers
retroviral vector for gene as a last resort when more
therapy was developed by traditional treatments, like
Richard Mulligan, a chemotherapy, don’t work.
researcher at Massachusetts Kymriah treats a bone
Institute of Technology and marrow cancer that affects
former doctoral student of children and young adults,
Paul Berg, a key pioneer in and Yescarta treats a type
genetic engineering at of lymphoma. Some
Stanford University. patients have had
remarkable recoveries and
Despite the difficulties, gene remain in remission
therapy began to turn a months or years later.
corner the following decade,
aided by the arrival of safer Building new skin
and more effective vectors. When a bacterial infection
Positive results began to be threatened his life, a boy
reported for a number of with a devastating
gene therapy trials. Most connective tissue disorder
were small-scale academic called epidermolysis
studies. In 2007 Jean bullosa got new skin
Bennett, an ophthalmologist created with gene therapy.
at the University of To make it, scientists
Pennsylvania, demonstrated extracted cells from a part
in a small trial that gene of the child’s body that
therapy could provide a wasn’t blistered. They
promising treatment for isolated skin stem cells
inherited retinal disease. and added copies of a
In 2015 Subsequent trials in healthy version of the
more patients carried out, gene. They let these cells
gene therapy was found to grow into small sheets
help haemophilic patients, a and, in a series of three
number of whom no longer surgeries, transplanted
needed to take blood clotting them onto the patient’s
factor drugs. In 2016 Europe body at a hospital in
licensed a second gene Germany. Researchers
therapy, developed by announced the
GlaxoSmithKline for children groundbreaking skin graft
suffering from ADA-SCID. A in November.
year later Novartis secured
approval for the first gene
therapy in the United States.
All these scientist worked
hard to develop gene therapy
and through decades of
research and study, it was
successfully developed. In
the near future, as scientist
continue to widen their study
regarding with gene therapy,
we are all hoping for a
successful outcome that
would benefit us all.

a.) Gene therapy involves the manipulation of genes to fight or prevent diseases. Put simply,
it introduces a "good" gene into a person who has a disease caused by a "bad" gene. Gene
therapy does have risks and limitations. The viruses and other agents used to deliver the
"good" genes can affect more than the cells for which they're intended. If a gene is added to
DNA, it could be put in the wrong place, which could potentially cause cancer or other
damage.

b.) Enhancing humans is still in the future, but the basic argument in favor of doing so is that
it could make life better in significant ways by enhancing certain characteristics of people.
We value intelligence, beauty, strength, endurance, and certain personality characteristics
and behavioral tendencies, and if these traits were found to be due to a genetic component
we could enhance people by giving them such features. Advocates of genetic engineering
point out that many people try to improve themselves in these ways already by diet,
exercise, education, cosmetics, and even plastic surgery. People try to do these things for
themselves, and parents try to provide these things for their children. If exercising to
improve strength, agility, and overall fitness is a worthwhile goal, and if someone is praised
for pursuing education to increase their mental capabilities, then why would it not be
worthwhile to accomplish this through genetics? Genetic engineering for enhancement is
still a ways off of such this traits.

c.)Gene therapy has some potential risks. A gene can't easily be inserted directly into your
cells. Rather, it usually has to be delivered using a carrier, called a vector. The most common
gene therapy vectors are viruses because they can recognize certain cells and carry genetic
material into the cells' genes. Researchers remove the original disease-causing genes from
the viruses, replacing them with the genes needed to stop disease.

Gene therapy is has 100% assurance, finding a reliable way to get genetic material into cells,
targeting the correct cells, reducing the risk of side effects. In my opinion, I would still try to
submit myself even if it's not 100% sure that it can treat me, since as what I've researched,
mostly who got gene therapy are cured or enhanced.

Das könnte Ihnen auch gefallen